Matinas Biopharma Holdings, Inc. current report, 07 November 2023

Full document

Business Context and Reporting Period

Company: Matinas Biopharma Holdings, Inc. (MTNB)
Filing Type: Form 8-K (Current Report)
Date of Report: November 7, 2023
Event: Announcement of positive results from an in vivo animal study of the Company's oral lipid nanocrystal (LNC) formulation of docetaxel.

Key Financial Metrics

This filing is a current report regarding a scientific development event and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes and Study Results

The Company reported significant preclinical findings regarding its oral LNC docetaxel formulation in a syngeneic mouse melanoma model (B16F10 cells). Key results include:

  • Efficacy: Daily oral LNC docetaxel demonstrated tumor volume reductions comparable to intravenous (IV) docetaxel at Day 14.
    • High-dose oral LNC: -63% reduction
    • Low-dose oral LNC: -57% reduction
    • IV docetaxel control: -68% reduction
  • Safety: No systemic toxicities were observed over the 10-day oral dosing period. Body weight remained stable, and hematologic parameters were similar to untreated controls.
  • Comparison: The oral formulation achieved efficacy similar to the standard IV administration, which is currently associated with significant side effects.

Outlook, Management Commentary, and Risks

Future Plans:

  • The Company intends to evaluate the current LNC docetaxel formulation in other tumor models.
  • Longer-term treatment regimens will be assessed to confirm the lack of toxicity.
  • Plans include evaluating the anti-tumor activity of LNC formulations of small oligonucleotides.
Risks and Forward-Looking Statements:
  • All product candidates are in the development stage and not available for sale.
  • Success depends on obtaining additional capital to meet liquidity needs and complete clinical trials.
  • Risks include uncertainties in clinical testing, regulatory approval timing and costs, intellectual property protection, and competition.

Investor Verification Checklist

  • Verify the Company's current cash position and runway to fund future clinical trials, as this filing highlights capital needs as a key risk.
  • Confirm the timeline for transitioning from animal studies to human clinical trials for the oral docetaxel formulation.
  • Review the specific details of the "longer-term treatment regimens" planned to validate safety beyond the 10-day study period.
  • Monitor upcoming regulatory interactions regarding the LNC platform technology.